Showing results (1-10 of 72) with videos related to
Sort By:
Pageof 8
Oncotargets and Therapy|July 7, 2016
The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibTheresa M Medina, Karl D LewisTherapeutic Advances in Medical Oncology|January 27, 2022
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes againChristina M Davis, Karl D LewisCore Evidence|November 3, 2010
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based reviewSonia Okuyama, Rene Gonzalez, Karl D LewisExpert Opinion on Investigational Drugs|October 17, 2008
PI-88: a novel inhibitor of angiogenesisRagini Kudchadkar, Rene Gonzalez, Karl D LewisTherapeutic Advances in Medical Oncology|September 30, 2011
Therapeutic options in cutaneous melanoma: latest developmentsRodabe N Amaria, Karl D Lewis, Rene GonzalezInternational Journal of Dermatology|April 2, 2009
Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literatureMayumi Fujita, Whitney A High, Shabnam Asgari, et al.Clinical Nuclear Medicine|May 10, 2013
Anti-CTLA4 antibody therapy related complications on FDG PET/CTPhillip J Koo, William C Klingensmith, Karl D Lewis, et al.Investigational New Drugs|October 16, 2009
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanomaKarl D Lewis, Wolfram Samlowski, John Ward, et al.Cancer Investigation|August 17, 2005
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFKarl D Lewis, Peter Gibbs, Steven O'Day, et al.JCO Precision Oncology|February 17, 2022
Acral Lentiginous Melanoma Harboring a <i>ROS1</i> Gene Fusion With Clinical Response to EntrectinibKasey L Couts, Caroline E McCoach, Danielle Murphy, et al.Pageof 8